LENZ Therapeutics is betting big on a newly approved eye drop that could help people with age-related trouble reading up close, and it plans to start selling it soon. The upside hinges on whether patients and doctors switch from an existing option—and whether a one-product company can avoid surprises once the drug is widely used.Read more
Catalysts About LENZ Therapeutics LENZ Therapeutics is a commercial-stage biopharma company focused on VIZZ, an aceclidine-based eye drop for presbyopia in adults. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About LENZ Therapeutics LENZ Therapeutics develops and commercializes innovative ophthalmic therapies, led by VIZZ, a novel eye drop for presbyopia. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About LENZ Therapeutics LENZ Therapeutics develops and commercializes ophthalmic therapies, including VIZZ, a pharmacologic eye drop for the treatment of presbyopia in adults. What are the underlying business or industry changes driving this perspective?Read more
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
